Skip to main content

GLP-1 drugs

FDA recalls

6 rows

DateCompany and reasonClass
Aug 27, 2026Amneal Pharmaceuticals of New York, LLC
Defective Delivery System: Possibility of no medication in the prefilled pen.		Class II · Ongoing
Apr 23, 2026Lupin Pharmaceuticals Inc.
Presence of particulate matter: a white thread-like structure in the cartridge		Class II · Ongoing
Apr 4, 2022Cardinal Health Inc.
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions		Class II · Completed
Aug 18, 2021Eli Lilly & Company
Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.		Class II · Terminated
Mar 21, 2021Novo Nordisk Inc
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.		Class II · Terminated
Mar 14, 2021Cardinal Health Inc.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.		Class II · Terminated

← Back to GLP-1 drugs

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).